[go: up one dir, main page]

AR094018A1 - FUNNY CURRENT INHIBITORS (IF) FOR USE IN A METHOD OF TREATMENT AND / OR PREVENTION OF CARDIAC DISEASE IN CANINOS - Google Patents

FUNNY CURRENT INHIBITORS (IF) FOR USE IN A METHOD OF TREATMENT AND / OR PREVENTION OF CARDIAC DISEASE IN CANINOS

Info

Publication number
AR094018A1
AR094018A1 ARP130104746A ARP130104746A AR094018A1 AR 094018 A1 AR094018 A1 AR 094018A1 AR P130104746 A ARP130104746 A AR P130104746A AR P130104746 A ARP130104746 A AR P130104746A AR 094018 A1 AR094018 A1 AR 094018A1
Authority
AR
Argentina
Prior art keywords
arrhythmias
prevention
treatment
funny current
caninos
Prior art date
Application number
ARP130104746A
Other languages
Spanish (es)
Inventor
Lang Ingo
Christian Meil Joerg
Seidler Randolph
Markert Michael
Kley Saskia
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of AR094018A1 publication Critical patent/AR094018A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un bloqueante lᶠ, o una de sus sales farmacéuticamente aceptables para el tratamiento y/o prevención de un paciente canino que sufre de enfermedades cardíacas, con preferencia enfermedades cardíacas tales como cardiomiopatía dilatada (DCM), insuficiencia de la válvula mitral (MI), arritmias, con preferencia taquiarritmias, arritmias con preferencia arritmias atriales, arritmias atrioventriculares nodales y/o taquicardia. Reivindicación 14: El inhibidor de corriente funny (lᶠ) o una de sus sales farmacéuticamente aceptables para usar en un método de acuerdo con cualquiera de las reivindicaciones 12 a 13, caracterizado porque el inhibidor de corriente funny (Iᶠ) se selecciona del grupo que consiste en cilobradina, zatebradina, ivabradina y anilidina, con preferencia es cilobradina.A lᶠ blocker, or one of its pharmaceutically acceptable salts for the treatment and / or prevention of a canine patient suffering from heart disease, preferably heart disease such as dilated cardiomyopathy (DCM), mitral valve insufficiency (MI), arrhythmias , preferably tachyarrhythmias, arrhythmias preferably atrial arrhythmias, nodal atrioventricular arrhythmias and / or tachycardia. Claim 14: The funny current inhibitor (lᶠ) or a pharmaceutically acceptable salt thereof for use in a method according to any of claims 12 to 13, characterized in that the funny current inhibitor (Iᶠ) is selected from the group consisting in cilobradine, zatebradine, ivabradine and anilidine, it is preferably cilobradine.

ARP130104746A 2012-12-14 2013-12-13 FUNNY CURRENT INHIBITORS (IF) FOR USE IN A METHOD OF TREATMENT AND / OR PREVENTION OF CARDIAC DISEASE IN CANINOS AR094018A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12197371 2012-12-14

Publications (1)

Publication Number Publication Date
AR094018A1 true AR094018A1 (en) 2015-07-01

Family

ID=47358383

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104746A AR094018A1 (en) 2012-12-14 2013-12-13 FUNNY CURRENT INHIBITORS (IF) FOR USE IN A METHOD OF TREATMENT AND / OR PREVENTION OF CARDIAC DISEASE IN CANINOS

Country Status (5)

Country Link
US (1) US20140171415A1 (en)
EP (1) EP2931262A1 (en)
AR (1) AR094018A1 (en)
TW (1) TW201436795A (en)
WO (1) WO2014090842A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2741735A1 (en) 2011-08-12 2014-06-18 Boehringer Ingelheim Vetmedica GmbH Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
WO2017173458A1 (en) * 2016-04-01 2017-10-05 Swiderski Cyprianna Compositions and methods targeting hcn channels for breathing therapeutics
ES2851923T3 (en) * 2016-05-20 2021-09-09 Nestle Sa Intermediate chain triglycerides for the treatment of degenerative mitral valve disease in companion animals
ES2963110T3 (en) * 2018-12-27 2024-03-25 Nestle Sa Compositions and methods for the diagnosis and treatment of degenerative mitral valve disease in canines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
WO2014090842A1 (en) 2014-06-19
TW201436795A (en) 2014-10-01
EP2931262A1 (en) 2015-10-21
US20140171415A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
MX2015017865A (en) Pyrimidinedione compounds against cardiac conditions.
CL2017001871A1 (en) 4-Methylsulfonyl-substituted urea piperidine compounds for the treatment of dilated cardiomyopathy (mcd)
IL234181B (en) A method for mapping early ventricular/atrial beats during sinus rhythm
CY1118839T1 (en) COVERED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIBE
EP2498797A4 (en) TREATMENT OF HEART DISEASES
UY34305A (en) DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
CL2017000866A1 (en) Compounds and compositions for the treatment or prevention of pathological disorders associated with excess deposition of fibrin and / or thrombus formation
CY1123056T1 (en) NEW FORM OF ADMINISTRATION OF RACECADOTRIL
CL2019002900A1 (en) Benzoazepine analogs as bruton tyrosine kinase inhibitors.
MX346730B (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY HYPERTENSION.
PE20141452A1 (en) AVIRULENT MODIFIED SALMONELLA GALLINARUM STRAINS AND PHARMACEUTICAL COMPOSITIONS THAT USE THEM
MX362098B (en) Treatment of peripheral vascular disease using umbilical cord tissue-derived cells.
MX2013002390A (en) Treatment of myocardial infarction using tgf - beta antagonists.
MX2017016347A (en) Combination therapy of cardiac myosin activator and sinus node if current inhibitor.
UY36416A (en) 1- [2- (AMINOMETIL) BENCIL] -2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PIRROLO [3,2-D] PYRIMIDIN-4-WAVES AS INHIBITORS OF MYELOPEROXIDASE
AR094018A1 (en) FUNNY CURRENT INHIBITORS (IF) FOR USE IN A METHOD OF TREATMENT AND / OR PREVENTION OF CARDIAC DISEASE IN CANINOS
CY1118294T1 (en) DAVIGATRANAN CARBOXYLIC ACID ESTIMES OF DAVIGATRANAN AS PRODUCTS AND THEIR USE AS MEDICINE
EA201291431A1 (en) COMPOSITION FOR HAIR STORAGE
EA201692518A3 (en) METHODS TO IMPROVE MYOCARDIAL PERFORMANCE IN PATIENTS AFTER FONTENE OPERATION USING UDENAFIL COMPOSITIONS
AR105752A1 (en) METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
WO2015074010A3 (en) Compositions and methods for cardiac regeneration
CL2013000021A1 (en) Delta crystalline form of perindopril arginine salt; preparation procedure; pharmaceutical compositions containing it; and its use for the treatment of cardiovascular diseases, such as high blood pressure, heart failure or stable coronary heart disease.
MX2018004380A (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer.
CY1118645T1 (en) USE OF PIDOTIMOD IN HEALTH TREATMENT
ES2721003T3 (en) Use of 1,3-propane disulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure